Drugs / disaccharide tripeptide glycerol dipalmitoyl
disaccharide tripeptide glycerol dipalmitoyl
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00003667 | Sep 1998 → Aug 2000 | sarcoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00038142 | Nov 1997 → Mar 2016 | Ewing sarcoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | disaccharide tripeptide glycerol dipalmitoyl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003667 ↗ |
| Known as | Dtp-gdp | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297391 ↗ |
| Known as | ImmTher | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00038142 ↗ |
| Modality | Small molecule | — CHEMBL4297391 ↗ |
| Route | Intravenous | “ImmTher 900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.” NCT00038142 ↗ |